Glucocorticoid-sparing effect of first-year anti-TNFα treatment in rheumatoid arthritis (CORPUS Cohort).

Date publication

mai 2017

Journal

Clinical and experimental rheumatology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GUILLEMIN Francis

Tous les auteurs :
Duquenne C, Wendling D, Sibilia J, Job-Deslandre C, Guillevin L, Benichou J, Flipo RM, Guillemin F, Saraux A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28516872

Résumé

Anti-TNFα agents are indicated in selected patients with rheumatoid arthritis (RA) who respond inadequately to methotrexate and particularly when glucocorticoids are mandatory. We evaluated whether a glucocorticoid-sparing effect occurred during the first year of anti-TNF-α therapy.

Mots clés

Adult, Aged, Antirheumatic Agents, therapeutic use, Arthritis, Rheumatoid, drug therapy, Autoantibodies, immunology, C-Reactive Protein, immunology, Cohort Studies, Drug Therapy, Combination, Female, Glucocorticoids, therapeutic use, Humans, Injections, Intra-Articular, Longitudinal Studies, Male, Methotrexate, therapeutic use, Middle Aged, Multivariate Analysis, Peptides, Cyclic, immunology, Prednisone, therapeutic use, Prospective Studies, Rheumatoid Factor, immunology, Tumor Necrosis Factor-alpha, antagonists & inhibitors

Référence

Clin. Exp. Rheumatol.. 2017 May;: